CorMedix Inc. (FRA:19KA)
Germany · Delayed Price · Currency is EUR | Market Cap | 546.39M -27.7% |
| Revenue (ttm) | 404.61M +280.5% |
| Net Income | 162.82M +265.9% |
| EPS | 1.86 +163.5% |
| Shares Out | n/a |
| PE Ratio | 3.77 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 250 |
| Open | 7.00 |
| Previous Close | 6.70 |
| Day's Range | 7.00 - 7.00 |
| 52-Week Range | 5.20 - 11.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 11, 2026 |
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New... [Read more]
News
CorMedix announces FDA acceptance for Priority Review of Rezzayo sNDA
CorMedix (CRMD) announced that the FDA has accepted for filing the supplemental new drug application, or sNDA, seeking approval of Rezzayo for the prophylaxis of invasive fungal disease. The sNDA…
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
PARSIPPANY, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New D...
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the...
CorMedix initiated with an Outperform at Oppenheimer
Oppenheimer analyst Les Sulewski initiated coverage of CorMedix (CRMD) with an Outperform rating and $15 price target Investors appear “overly focused” on DefenCath’s near-term post-TDAPA revenue decl...
CorMedix Transcript: Wells Fargo 21st Annual Healthcare Conference
The company has rapidly evolved into a diversified specialty pharma with eight marketed products and a scalable institutional platform. DefenCath's reimbursement transition and Medicare Advantage focus, REZZAYO's expanded market potential, and robust financials position the firm for further growth and strategic acquisitions.
CorMedix Slides: Corporate presentation
CorMedix has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threateni...
CorMedix reports Q2 EPS 29c vs. 28c last year
Reports Q2 revenue $101.93M, consensus $96.05M. Joseph Todisco, CorMedix (CRMD) chairman and CEO, commented, “CorMedix delivered a strong second quarter, generating $101.9 million in consolidated reve...
CorMedix Earnings Call Transcript: Q2 2026
Q2 2026 revenue surged to $101.9M, driven by DefenCath and Melinta portfolio, with net income of $26M and adjusted EBITDA of $58.7M. Full-year guidance was reaffirmed and raised, while new supply agreements and positive clinical data support long-term growth.
CorMedix Earnings release: Q2 2026
CorMedix released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
CorMedix Quarterly report: Q2 2026
CorMedix has published its Q2 2026 quarterly earnings report on August 13, 2026.
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒...
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before th...
CorMedix price target lowered to $13 from $14 at RBC Capital
RBC Capital lowered the firm’s price target on CorMedix (CRMD) to $13 from $14 and keeps an Outperform rating on the shares as part of a broader research note previewing…
CorMedix Transcript: AGM 2026
The meeting saw the election of all director nominees, approval of executive compensation, and auditor ratification. Five charter-related proposals failed to pass. No questions were raised by stockholders during the session.
CorMedix announces United States Court of Appeals affirms patent judgements
CorMedix (CRMD) announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the Northern District of Illinois that…
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of th...
CorMedix Transcript: Jefferies Global Healthcare Conference 2026
Management highlighted a transformation from a single-asset to a diversified institutional care company, driven by the Melinta acquisition and pipeline expansion. Key products REZZAYO and DefenCath are positioned for growth, with reimbursement and legislative changes as major catalysts. Guidance anticipates higher 2027 sales and continued business development.
CorMedix Slides: Corporate presentation
CorMedix has posted slides in relation to its latest quarterly earnings report, which was published on May 22, 2026.
CorMedix Transcript: RBC Capital Markets Global Healthcare Conference 2026
Preliminary REZZAYO data show efficacy and safety differentiation, with a broad FDA label sought and sNDA submission planned for H2. DefenCath guidance was raised on strong utilization, with 2027 revenue expected to rise as CMS reimbursement improves. Policy advocacy and pipeline expansion continue.
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Ca...
CorMedix Earnings Call Transcript: Q1 2026
Q1 2026 saw net revenue of $127.4M and adjusted EBITDA of $70M, driven by DefenCath and Melinta portfolio growth. Full-year guidance was raised for revenue and EBITDA, with DefenCath expected to see price changes post-reimbursement transition. REZZAYO's positive phase III results support an sNDA filing in H2 2026.
CorMedix Earnings release: Q1 2026
CorMedix released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
CorMedix Quarterly report: Q1 2026
CorMedix has published its Q1 2026 quarterly earnings report on May 14, 2026.
CorMedix reports Q1 EPS 43c, consensus 33c
Reports Q1 revenue $127.43M, consensus $104.96M. Joseph Todisco, CorMedix (CRMD) chairman and CEO, commented, “CorMedix has entered 2026 with strong momentum across all areas of our business. DefenCat...